Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.49 |
| ▸ | MMP13 | P45452 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8361646 | 0.92 | MMP2 (0.51) | MMP2MMP13KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6572436 | 0.89 | MMP2 (0.53) | MMP2MMP13KMT2ASMN1; SMN2MAPT | |
| SCHEMBL8363785 | 0.88 | MMP2 (0.51) | MMP2MMP13KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5898961 | 0.87 | MMP2 (0.52) | MMP2MMP13KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5898944 | 0.86 | MMP2 (0.54) | MMP2MMP13KMT2ASMN1; SMN2MAPT | |
| SCHEMBL8361686 | 0.86 | MMP2 (0.47) | MMP2MMP13KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5899028 | 0.85 | MMP2 (0.55) | MMP2MMP13KMT2ASMN1; SMN2MAPT | |
| SCHEMBL8361708 | 0.85 | MMP2 (0.52) | MMP2MMP13KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5898986 | 0.84 | MMP13 (0.69) | MMP2MMP13KMT2ASMN1; SMN2MAPT | |
| SCHEMBL8361679 | 0.84 | MMP13 (0.64) | MMP2MMP13KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115632-B1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1406602-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406626-A2 | SULPHONYL ARYL HYDROXAMATES AND THEIR USE AS MMP INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6683078-B2 | REDUCING DEGRADATION OF CONNECTIVE TISSUE DUE TO CANCER OR INFLAMMATION | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | PHARMACIA CORPORATION | 2003-09-11 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007930-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | ARSA, AADAC, ASPH | MMP2 27/4885MMP13 26/4885KMT2A 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.